SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)
$NBIX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | $213.00 | Buy | Goldman |
| 5/22/2026 | $221.00 | Outperform | Bernstein |
| 2/24/2026 | $160.00 | Outperform | Wolfe Research |
| 1/8/2026 | $175.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/21/2025 | $175.00 | Buy | Citigroup |
| 7/21/2025 | $163.00 | Buy | Truist |
| 7/10/2025 | $182.00 | Buy | Goldman |
| 4/15/2025 | $138.00 | Hold → Buy | Needham |
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
Goldman resumed coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $213.00
Bernstein initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $221.00
Wolfe Research initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $160.00
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
144 - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con
SAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executive Management Committee. As Chief Business Officer, Siddhanti will lead Neurocrine's enterprise growth strategy, overseeing business development, corporate strategy, alliance management and program management to maximize the value of the company's expanding pipeline through both internal innovation and strategic external opportunities.Since joining Neurocrine in 2017, Siddhanti has assumed leadership roles of increasing responsibilit
Conference Call and Webcast Scheduled for Thursday, July 30SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026. The schedule for the press release and conference call / webcast is as follows:Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-347-6865International Dial-In Number: 203-518-9757Conference ID: NBIXTh
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH. "Infants and young children with classic CAH face significant health
Conference Call and Webcast Scheduled for Thursday, July 30SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026. The schedule for the press release and conference call / webcast is as follows:Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-347-6865International Dial-In Number: 203-518-9757Conference ID: NBIXTh
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-YearAnnounced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA® (valbenazine) Net Sales Guidance of $2.7 - $2.8 BillionSAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2026.
Conference Call and Webcast Scheduled for Tuesday, May 5SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2026. The schedule for the press release and conference call / webcast is as follows:Q1 2026 Press Release: May 5, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ1 2026 Conference Call: May 5, 2026 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-274-8461International Dial-In
SAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executive Management Committee. As Chief Business Officer, Siddhanti will lead Neurocrine's enterprise growth strategy, overseeing business development, corporate strategy, alliance management and program management to maximize the value of the company's expanding pipeline through both internal innovation and strategic external opportunities.Since joining Neurocrine in 2017, Siddhanti has assumed leadership roles of increasing responsibilit
Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period. Richard is an accomplished leader with over 30 years' senior finance and strategic experience within
SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies. Dr. Ratz – who joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device – previously spent nearly 30 year
SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)